X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
miRagen gains Viridian's clinical stage anti-IGF-1R monoclonal antibody, VRDN-001, a clinical-stage insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) to treat thyroid eye disease.
Lead Product(s): VRDN-001
Therapeutic Area: Immunology Product Name: AVE-1642
Highest Development Status: IND EnablingProduct Type: Large molecule
Recipient: Viridian Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 28, 2020
Details:
Company plans to use private placement financing proceeds of $91 million to advance multiple compounds through phase 2 proof of concept studies in TED and to expand its orphan disease pipeline.
Lead Product(s): VRDN-001
Therapeutic Area: Immunology Product Name: AVE-1642
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Fairmount Funds Management LLC
Deal Size: $91.0 million Upfront Cash: Undisclosed
Deal Type: Financing October 28, 2020
Details:
Cobomarsen lacks a compelling result for the study's primary endpoint, objective skin response of at least four months duration (ORR4) relative to the vorinostat control arm.
Lead Product(s): Cobomarsen
Therapeutic Area: Oncology Product Name: MRG-106
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2020
Details:
Data demonstrate that a single systemic dose of MRG-110 reduced detectable miR-92a levels in the peripheral blood of humans and led to the regulation of several well established miR-92a target genes.
Lead Product(s): MRG-110
Therapeutic Area: Cardiology/Vascular Diseases Product Name: MRG-110
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2020
Details:
Cobomarsen is an inhibitor of miR-155 currently being developed by miRagen in two clinical programs to address different types of T-cell lymphoma, including a Phase 2 trial for cutaneous T-cell lymphoma (CTCL) and a Phase 1 trial for adult T-cell leukemia/lymphoma (ATLL).
Lead Product(s): Cobomarsen
Therapeutic Area: Oncology Product Name: MRG-106
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 23, 2020
Details:
MRG-229 has demonstrated mechanistic biomarker regulation and antifibrotic activity in vitro using human model systems.
Lead Product(s): MRG-229
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: MRG-229
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2020
Details:
miRagen Therapeutics is conducting a Phase 1 trial of cobomarsen in adult T-cell leukemia/lymphoma (ATLL).
Lead Product(s): Cobomarsen
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 23, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
